Review explores evidence for personalized T2D pharmacotherapy including patient characteristics that predict optimal response to GLP-1 drugs versus other medication classes.
Key findingReview explores evidence for personalized T2D pharmacotherapy including patient characteristics that
What the researchers found
Review explores evidence for personalized T2D pharmacotherapy including patient characteristics that predict optimal response to GLP-1 drugs versus other medication classes.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Systematic review examining dysregulated miRNA expression detected in various patient samples and their correlation with drug response.
How the study worked
In publication.
Who was studied
Type 2 diabetes patients across microRNA biomarker studies
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.
Journal of personalized medicine, 15(11)
Citation
Altabas, Velimir; Marinković Radošević, Jelena. (2025). Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes-A Systematic Review.. Journal of personalized medicine, 15(11). https://doi.org/10.3390/jpm15110539